Newer insulin regimens that closely mimic physiologic response, such as basal insulin degludec and glargine U-300 as well as the fast-acting insulin aspart (FIAsp) and ultra-rapid lispro (URLi) along with advances in insulin injection devices, also simplified insulin therapy while reducing the risk of hypoglycemia [1, 2]. The gene discussed is INS; the disease is Hypoglycemia.